At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Vaccinating Children After Chemotherapy for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study
In Brief
A Phase 4 clinical trial evaluating Prevnar®13, Pneumovax® 23, and 1 other intervention for Acute Lymphoblastic Leukemia. Completed, enrolled 156 participants across 1 site.
Detailed Summary
This multi-center open label clinical trial aims to identify predictors of low antibody titers to vaccine antigens in children with ALL who completed chemotherapy in the prior 6 months, and to determine the immunogenicity and safety of diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis-Haemophilus influenzae type b (DTaP-IPV-Hib) and 13-valent pneumococcal conjugate vaccine (PCV13) booster immunization administered 6 months post-chemotherapy, followed by 23-valent pneumococcal polysaccharide vaccination (PPV23) 2 months later. The results will support the development of clinical practice guidelines for this population.
Study Details
Timeline
Interventions
A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.
A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13
A single dose of Pediacel® will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.